Skip to main content
Erschienen in: Tumor Biology 9/2015

01.09.2015 | Research Article

RETRACTED ARTICLE: MiRNA-494 inhibits metastasis of cervical cancer through Pttg1

verfasst von: Bing Chen, Zhaohui Hou, Chundong Li, Ying Tong

Erschienen in: Tumor Biology | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Many cervical cancer (CC) patients experience early cancer metastasis, resulting in poor therapeutic outcome after resection of primary cancer. Hence, there is a compelling requirement for understanding of the molecular mechanisms underlying the invasiveness control of CC. Pituitary tumor-transforming gene 1 (Pttg1) has been recently reported to promote cancer cell growth and metastasis in a number of various tumors. However, its regulation by microRNAs (miRNAs) as well as its role in CC have not been clarified. Here, we reported significantly higher levels of Pttg1 and significantly lower levels of miR-494 in the resected CC tissue, compared with the adjacent normal cervical tissue from the same patient. Interestingly, Pttg1 levels inversely correlated with miR-494 levels. In vitro, Pttg1 levels determined CC cell invasiveness and were inhibited by miR-494 levels. However, miR-494 levels were not affected by Pttg1 levels. Furthermore, miR-494 inhibited Pttg1 expression in CC cells, through directly binding and inhibition on 3′-UTR of Pttg1 mRNA. Together, our data suggest that Pttg1 may increase CC cell metastasis, which is negatively regulated by miR-494. Our work thus highlights a novel molecular regulatory machinery in metastasis of CC.
Literatur
1.
Zurück zum Zitat Kanayama T, Mabuchi S, Fujita M, Kimura T. Calcaneal metastasis in uterine cervical cancer: a case report and a review of the literature. Eur J Gynaecol Oncol. 2012;33:524–5.PubMed Kanayama T, Mabuchi S, Fujita M, Kimura T. Calcaneal metastasis in uterine cervical cancer: a case report and a review of the literature. Eur J Gynaecol Oncol. 2012;33:524–5.PubMed
2.
Zurück zum Zitat Setoodeh R, Hakam A, Shan Y. Cerebral metastasis of cervical cancer, report of two cases and review of the literature. Int J Clin Exp Pathol. 2012;5:710–4.PubMedPubMedCentral Setoodeh R, Hakam A, Shan Y. Cerebral metastasis of cervical cancer, report of two cases and review of the literature. Int J Clin Exp Pathol. 2012;5:710–4.PubMedPubMedCentral
3.
Zurück zum Zitat Peters P, Bandi H, Efendy J, Perez-Smith A, Olson S. Rapid growth of cervical cancer metastasis in the brain. J Clin Neurosci. 2010;17:1211–2.CrossRefPubMed Peters P, Bandi H, Efendy J, Perez-Smith A, Olson S. Rapid growth of cervical cancer metastasis in the brain. J Clin Neurosci. 2010;17:1211–2.CrossRefPubMed
4.
Zurück zum Zitat Chen B, Zhang C, Dong P, Guo Y, Mu N. Molecular regulation of cervical cancer growth and invasion by VEGFA. Tumour Biol. 2014;35:11587–93.CrossRefPubMed Chen B, Zhang C, Dong P, Guo Y, Mu N. Molecular regulation of cervical cancer growth and invasion by VEGFA. Tumour Biol. 2014;35:11587–93.CrossRefPubMed
5.
Zurück zum Zitat Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S. Pituitary tumor transforming gene (pttg) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol. 2000;14:1137–46.CrossRefPubMed Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S. Pituitary tumor transforming gene (pttg) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol. 2000;14:1137–46.CrossRefPubMed
6.
Zurück zum Zitat Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, et al. Down-regulation of the pttg1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochem Pharmacol. 2012;84:598–611.CrossRefPubMed Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, et al. Down-regulation of the pttg1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochem Pharmacol. 2012;84:598–611.CrossRefPubMed
7.
Zurück zum Zitat Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev. 2007;28:165–86.CrossRefPubMed Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev. 2007;28:165–86.CrossRefPubMed
8.
Zurück zum Zitat Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N. The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res. 2006;4:130–7.CrossRefPubMedPubMedCentral Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N. The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res. 2006;4:130–7.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat El-Naggar SM, Malik MT, Kakar SS. Small interfering RNA against Pttg: a novel therapy for ovarian cancer. Int J Oncol. 2007;31:137–43.PubMed El-Naggar SM, Malik MT, Kakar SS. Small interfering RNA against Pttg: a novel therapy for ovarian cancer. Int J Oncol. 2007;31:137–43.PubMed
11.
Zurück zum Zitat Chen G, Li J, Li F, Li X, Zhou J, Lu Y, et al. Inhibitory effects of anti-sense Pttg on malignant phenotype of human ovarian carcinoma cell line SK-OV-3. J Huazhong Univ Sci Technol Med Sci = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban. 2004;24:369–72.CrossRefPubMed Chen G, Li J, Li F, Li X, Zhou J, Lu Y, et al. Inhibitory effects of anti-sense Pttg on malignant phenotype of human ovarian carcinoma cell line SK-OV-3. J Huazhong Univ Sci Technol Med Sci = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban. 2004;24:369–72.CrossRefPubMed
12.
Zurück zum Zitat Yan S, Zhou C, Lou X, Xiao Z, Zhu H, Wang Q, et al. Pttg overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Cancer Res. 2009;69:3283–90.CrossRefPubMed Yan S, Zhou C, Lou X, Xiao Z, Zhu H, Wang Q, et al. Pttg overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Cancer Res. 2009;69:3283–90.CrossRefPubMed
13.
Zurück zum Zitat Zhou C, Liu S, Zhou X, Xue L, Quan L, Lu N, et al. Overexpression of human pituitary tumor transforming gene (hpttg), is regulated by beta-catenin/TCF pathway in human esophageal squamous cell carcinoma. Int J Cancer. 2005;113:891–8.CrossRefPubMed Zhou C, Liu S, Zhou X, Xue L, Quan L, Lu N, et al. Overexpression of human pituitary tumor transforming gene (hpttg), is regulated by beta-catenin/TCF pathway in human esophageal squamous cell carcinoma. Int J Cancer. 2005;113:891–8.CrossRefPubMed
14.
Zurück zum Zitat Shibata Y, Haruki N, Kuwabara Y, Nishiwaki T, Kato J, Shinoda N, et al. Expression of Pttg (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol. 2002;32:233–7.CrossRefPubMed Shibata Y, Haruki N, Kuwabara Y, Nishiwaki T, Kato J, Shinoda N, et al. Expression of Pttg (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol. 2002;32:233–7.CrossRefPubMed
15.
Zurück zum Zitat Zhang ML, Lu S, Zheng SS. Epigenetic changes of pituitary tumor-derived transforming gene 1 in pancreatic cancer. Hepatobil Pancreat Dis Int. 2008;7:313–7. Zhang ML, Lu S, Zheng SS. Epigenetic changes of pituitary tumor-derived transforming gene 1 in pancreatic cancer. Hepatobil Pancreat Dis Int. 2008;7:313–7.
16.
Zurück zum Zitat Ai J, Zhang Z, Xin D, Zhu H, Yan Q, Xin Z, et al. Identification of over-expressed genes in human renal cell carcinoma by combining suppression subtractive hybridization and cDNA library array. Sci China C Life Sci. 2004;47:148–57.CrossRefPubMed Ai J, Zhang Z, Xin D, Zhu H, Yan Q, Xin Z, et al. Identification of over-expressed genes in human renal cell carcinoma by combining suppression subtractive hybridization and cDNA library array. Sci China C Life Sci. 2004;47:148–57.CrossRefPubMed
17.
Zurück zum Zitat Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, et al. Hpttg, a human homologue of rat Pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hpttg. Oncogene. 1998;17:2187–93.CrossRefPubMed Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, et al. Hpttg, a human homologue of rat Pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hpttg. Oncogene. 1998;17:2187–93.CrossRefPubMed
18.
Zurück zum Zitat Zhou C, Tong Y, Wawrowsky K, Melmed S. Pttg acts as a stat3 target gene for colorectal cancer cell growth and motility. Oncogene. 2014;33:851–61.CrossRefPubMed Zhou C, Tong Y, Wawrowsky K, Melmed S. Pttg acts as a stat3 target gene for colorectal cancer cell growth and motility. Oncogene. 2014;33:851–61.CrossRefPubMed
19.
Zurück zum Zitat Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A, et al. Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis. 2007;28:749–59.CrossRefPubMed Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A, et al. Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis. 2007;28:749–59.CrossRefPubMed
20.
Zurück zum Zitat Huang SQ, Liao QJ, Wang XW, Xin DQ, Chen SX, Wu QJ, et al. RNAi-mediated knockdown of pituitary tumor-transforming gene-1 (Pttg1) suppresses the proliferation and invasive potential of PC3 human prostate cancer cells. Braz J Med Biol Res. 2012;45:995–1001.CrossRefPubMedPubMedCentral Huang SQ, Liao QJ, Wang XW, Xin DQ, Chen SX, Wu QJ, et al. RNAi-mediated knockdown of pituitary tumor-transforming gene-1 (Pttg1) suppresses the proliferation and invasive potential of PC3 human prostate cancer cells. Braz J Med Biol Res. 2012;45:995–1001.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Huang S, Liao Q, Li L, Xin D. Pttg1 inhibits smad3 in prostate cancer cells to promote their proliferation. Tumour Biol. 2014;35:6265–70.CrossRefPubMed Huang S, Liao Q, Li L, Xin D. Pttg1 inhibits smad3 in prostate cancer cells to promote their proliferation. Tumour Biol. 2014;35:6265–70.CrossRefPubMed
22.
Zurück zum Zitat Castilla C, Flores ML, Medina R, Perez-Valderrama B, Romero F, Tortolero M, et al. Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin Pttg1. Mol Cancer Ther. 2014;13:2372–83.CrossRefPubMed Castilla C, Flores ML, Medina R, Perez-Valderrama B, Romero F, Tortolero M, et al. Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin Pttg1. Mol Cancer Ther. 2014;13:2372–83.CrossRefPubMed
23.
Zurück zum Zitat Cao XL, Gao JP, Wang W, Xu Y, Shi HY, Zhang X. Expression of pituitary tumor transforming gene 1 is an independent factor of poor prognosis in localized or locally advanced prostate cancer cases receiving hormone therapy. Asian Pac J Cancer Prev. 2012;13:3083–8.CrossRefPubMed Cao XL, Gao JP, Wang W, Xu Y, Shi HY, Zhang X. Expression of pituitary tumor transforming gene 1 is an independent factor of poor prognosis in localized or locally advanced prostate cancer cases receiving hormone therapy. Asian Pac J Cancer Prev. 2012;13:3083–8.CrossRefPubMed
24.
Zurück zum Zitat Castilla C, Flores ML, Conde JM, Medina R, Torrubia FJ, Japon MA, et al. Downregulation of protein tyrosine phosphatase ptpl1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells. Clin Exp Metastasis. 2012;29:349–58.CrossRefPubMed Castilla C, Flores ML, Conde JM, Medina R, Torrubia FJ, Japon MA, et al. Downregulation of protein tyrosine phosphatase ptpl1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells. Clin Exp Metastasis. 2012;29:349–58.CrossRefPubMed
25.
Zurück zum Zitat Singh SV, Powolny AA, Stan SD, Xiao D, Arlotti JA, Warin R, et al. Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in tramp mice. Cancer Res. 2008;68:9503–11.CrossRefPubMedPubMedCentral Singh SV, Powolny AA, Stan SD, Xiao D, Arlotti JA, Warin R, et al. Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in tramp mice. Cancer Res. 2008;68:9503–11.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Bacac M, Provero P, Mayran N, Stehle JC, Fusco C, Stamenkovic I. A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One. 2006;1:e32.CrossRefPubMedPubMedCentral Bacac M, Provero P, Mayran N, Stehle JC, Fusco C, Stamenkovic I. A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One. 2006;1:e32.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Crosby ME, Jacobberger J, Gupta D, Macklis RM, Almasan A. E2f4 regulates a stable G2 arrest response to genotoxic stress in prostate carcinoma. Oncogene. 2007;26:1897–909.CrossRefPubMed Crosby ME, Jacobberger J, Gupta D, Macklis RM, Almasan A. E2f4 regulates a stable G2 arrest response to genotoxic stress in prostate carcinoma. Oncogene. 2007;26:1897–909.CrossRefPubMed
28.
Zurück zum Zitat Zhu X, Mao Z, Na Y, Guo Y, Wang X, Xin D. Significance of pituitary tumor transforming gene 1 (Pttg1) in prostate cancer. Anticancer Res. 2006;26:1253–9.PubMed Zhu X, Mao Z, Na Y, Guo Y, Wang X, Xin D. Significance of pituitary tumor transforming gene 1 (Pttg1) in prostate cancer. Anticancer Res. 2006;26:1253–9.PubMed
30.
Zurück zum Zitat Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMed Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMed
31.
Zurück zum Zitat He W, Li Y, Chen X, Lu L, Tang B, Wang Z, et al. Mir-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol. 2014;29:1427–34.CrossRefPubMed He W, Li Y, Chen X, Lu L, Tang B, Wang Z, et al. Mir-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol. 2014;29:1427–34.CrossRefPubMed
32.
Zurück zum Zitat Zhou RP, Chen G, Shen ZL, Pan LQ. Cinobufacin suppresses cell proliferation via mir-494 in BGC-823 gastric cancer cells. Asian Pac J Cancer Prev. 2014;15:1241–5.CrossRefPubMed Zhou RP, Chen G, Shen ZL, Pan LQ. Cinobufacin suppresses cell proliferation via mir-494 in BGC-823 gastric cancer cells. Asian Pac J Cancer Prev. 2014;15:1241–5.CrossRefPubMed
33.
Zurück zum Zitat Bai Y, Sun Y, Peng J, Liao H, Gao H, Guo Y, et al. Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of mir-494. Oncotarget. 2014;5:7760–75.CrossRefPubMedPubMedCentral Bai Y, Sun Y, Peng J, Liao H, Gao H, Guo Y, et al. Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of mir-494. Oncotarget. 2014;5:7760–75.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, et al. Mir-494 is regulated by ERK1/2 and modulates trail-induced apoptosis in non-small-cell lung cancer through bim down-regulation. Proc Natl Acad Sci U S A. 2012;109:16570–5.CrossRefPubMedPubMedCentral Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, et al. Mir-494 is regulated by ERK1/2 and modulates trail-induced apoptosis in non-small-cell lung cancer through bim down-regulation. Proc Natl Acad Sci U S A. 2012;109:16570–5.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Liborio-Kimura TN, Jung HM, Chan EK. Mir-494 represses hoxa10 expression and inhibits cell proliferation in oral cancer. Oral Oncol. 2015;51:151–7.CrossRefPubMed Liborio-Kimura TN, Jung HM, Chan EK. Mir-494 represses hoxa10 expression and inhibits cell proliferation in oral cancer. Oral Oncol. 2015;51:151–7.CrossRefPubMed
36.
Zurück zum Zitat Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam FW, et al. Mir-186, mir-3651 and mir-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014;31:1429–36.PubMed Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam FW, et al. Mir-186, mir-3651 and mir-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014;31:1429–36.PubMed
37.
Zurück zum Zitat Kwak SY, Yang JS, Kim BY, Bae IH, Han YH. Ionizing radiation-inducible mir-494 promotes glioma cell invasion through EGFR stabilization by targeting p190b RhoGap. Biochim Biophys Acta. 1843;2014:508–16. Kwak SY, Yang JS, Kim BY, Bae IH, Han YH. Ionizing radiation-inducible mir-494 promotes glioma cell invasion through EGFR stabilization by targeting p190b RhoGap. Biochim Biophys Acta. 1843;2014:508–16.
38.
Zurück zum Zitat Asuthkar S, Velpula KK, Nalla AK, Gogineni VR, Gondi CS, Rao JS. Irradiation-induced angiogenesis is associated with an mmp-9-mir-494-syndecan-1 regulatory loop in medulloblastoma cells. Oncogene. 2014;33:1922–33.CrossRefPubMed Asuthkar S, Velpula KK, Nalla AK, Gogineni VR, Gondi CS, Rao JS. Irradiation-induced angiogenesis is associated with an mmp-9-mir-494-syndecan-1 regulatory loop in medulloblastoma cells. Oncogene. 2014;33:1922–33.CrossRefPubMed
39.
Zurück zum Zitat Puck TT, Marcus PI, Cieciura SJ. Clonal growth of mammalian cells in vitro; growth characteristics of colonies from single Hela cells with and without a feeder layer. J Exp Med. 1956;103:273–83.CrossRefPubMedPubMedCentral Puck TT, Marcus PI, Cieciura SJ. Clonal growth of mammalian cells in vitro; growth characteristics of colonies from single Hela cells with and without a feeder layer. J Exp Med. 1956;103:273–83.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMed Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMed
41.
Zurück zum Zitat Solbach C, Roller M, Peters S, Nicoletti M, Kaufmann M, Knecht R. Pituitary tumor-transforming gene (Pttg): a novel target for anti-tumor therapy. Anticancer Res. 2005;25:121–5.PubMed Solbach C, Roller M, Peters S, Nicoletti M, Kaufmann M, Knecht R. Pituitary tumor-transforming gene (Pttg): a novel target for anti-tumor therapy. Anticancer Res. 2005;25:121–5.PubMed
42.
Zurück zum Zitat Yamanaka S, Campbell NR, An F, Kuo SC, Potter JJ, Mezey E, et al. Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma. Cell Cycle. 2012;11:2729–38.CrossRefPubMedPubMedCentral Yamanaka S, Campbell NR, An F, Kuo SC, Potter JJ, Mezey E, et al. Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma. Cell Cycle. 2012;11:2729–38.CrossRefPubMedPubMedCentral
Metadaten
Titel
RETRACTED ARTICLE: MiRNA-494 inhibits metastasis of cervical cancer through Pttg1
verfasst von
Bing Chen
Zhaohui Hou
Chundong Li
Ying Tong
Publikationsdatum
01.09.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 9/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3440-0

Weitere Artikel der Ausgabe 9/2015

Tumor Biology 9/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.